Mogrify and Sangamo in license agreement for ‘off-the-shelf’ CAR-Treg

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Ijeab)
(Image: Getty/Ijeab)

Related tags: Mogrify, Sangamo Therapeutics, CAR-Treg, Cell therapy

Sangamo plans to utilize Mogrify’s cell conversion technology to develop CAR-Treg cell therapies.

The two partners have entered into a collaboration and exclusive license agreement to use Mogrify’s proprietary induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) to develop allogeneic cell therapies.

Sangamo Therapeutics plans to utilize the stem cells with its zinc finger protein (ZFP) technology to create gene-engineered chimeric antigen receptor regulatory T cell (CAR-Treg) technology.

In return for the license to use Mogrify’s technology, Sangamo will pay an upfront fee and will be eligible to receive further additional milestone payments. A spokesperson was unable to reveal any further details on the financials.

Mogrify’s technology allows iPSCs and ESCs to be transformed using transcriptions factors or small molecules into any human cell type.

In the example of this agreement, Mogrify will be responsible for the discovery and optimization of iPSCs or ESCs to regulatory T cells, which can be transformed into novel ‘off-the-shell’ allogeneic CAR-Treg cell therapy candidates.

Mogrify states that this method of production potentially makes therapies more cost-effective.

A spokesperson told BioPharma-Reporter why this is: “The use of optimized transcription factor combinations helps to drive the change of the cell’s transcriptome and can, therefore, increase the efficiency (yield) and speed of conversion.

“This means more of the target cells can be made quicker and from a smaller amount of starting material. This includes both the source cell population and other necessary materials, such as culture media, which are costly.”

Jason Fontenot, head of cell therapy at Sangamo, stated that access to Mogrify’s technology diversifies the company’s options for developing CAR-Treg cell therapies.

In 2018, Sangamo acquired TxCell​ to gain the latter’s own CAR-Treg technology.

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us


View more